0 6 Sterol Sterol NNP 7 16 dependent dependent JJ 17 29 LDL-receptor LDL-receptor NNP 30 34 gene gene NN 35 48 transcription transcription NN 49 51 in in IN 52 63 lymphocytes lymphocyte NNS 64 68 from from IN 69 75 normal normal JJ 76 79 and and CC 80 83 CML CML NNP 84 92 patients patient NNS 92 93 . . . 95 101 Sterol Sterol NNP 102 112 regulatory regulatory JJ 113 120 element element NN 121 122 ( ( ( 122 125 SRE SRE NNP 125 126 ) ) ) 127 130 has have VBZ 131 135 been be VBN 136 146 recognized recognize VBN 147 149 to to TO 150 158 regulate regulate VB 159 166 various various JJ 167 170 key key JJ 171 176 genes gene NNS 177 183 coding cod VBG 184 187 for for IN 188 198 especially especially RB 199 202 low low JJ 203 210 density density NN 211 222 lipoprotein lipoprotein NN 223 224 ( ( ( 224 237 LDL)-receptor LDL)-receptor NNP 237 238 , , , 239 265 3-hydroxy-3-methylglutaryl 3-hydroxy-3-methylglutaryl NN 266 274 coenzyme coenzyme NN 275 276 A A NNP 277 278 ( ( ( 278 285 HMG-CoA HMG-CoA NNP 285 286 ) ) ) 287 296 reductase reductase NN 297 300 and and CC 301 308 HMG-CoA HMG-CoA NNP 309 317 synthase synthase NN 318 323 known know VBN 324 326 to to TO 327 331 play play VB 332 333 a a DT 334 341 crucial crucial JJ 342 346 role role NN 347 349 in in IN 350 353 the the DT 354 365 cholesterol cholesterol NN 366 374 feedback feedback NN 375 384 mechanism mechanism NN 384 385 . . . 386 389 The the DT 390 398 deranged derange VBN 399 410 cholesterol cholesterol NN 411 419 feedback feedback NN 420 429 mechanism mechanism NN 430 433 has have VBZ 434 438 been be VBN 439 445 widely widely RB 446 456 recognised recognise VBN 457 459 in in IN 460 470 initiation initiation NN 471 473 as as RB 474 478 well well RB 479 481 as as IN 482 493 progression progression NN 494 496 of of IN 497 504 various various JJ 505 510 types type NNS 511 513 of of IN 514 521 cancers cancer NNS 522 531 including include VBG 532 539 chronic chronic JJ 540 547 myeloid myeloid JJ 548 557 leukaemia leukaemia NN 558 559 ( ( ( 559 562 CML CML NNP 562 563 ) ) ) 563 564 . . . 565 577 Consequently consequently RB 577 578 , , , 579 582 the the DT 583 590 present present JJ 591 596 study study NN 597 600 was be VBD 601 610 addressed address VBN 611 613 to to TO 614 624 understand understand VB 625 629 this this DT 630 640 phenomenon phenomenon NN 641 644 and and CC 645 653 revealed reveal VBD 654 657 the the DT 658 667 existence existence NN 668 670 of of IN 671 672 a a DT 673 679 unique unique JJ 680 682 47 47 CD 683 686 kDa kda NN 687 694 protein protein NN 695 701 factor factor NN 702 708 having have VBG 709 717 affinity affinity NN 718 721 for for IN 722 726 this this DT 727 730 SRE SRE NNP 731 739 sequence sequence NN 740 742 in in IN 743 754 lymphocytes lymphocyte NNS 755 759 from from IN 760 766 normal normal JJ 767 775 subjects subject NNS 776 778 as as RB 779 783 well well RB 784 786 as as IN 787 790 its its PRP$ 791 798 absence absence NN 799 801 in in IN 802 813 lymphocytes lymphocyte NNS 814 818 from from IN 819 828 untreated untreated JJ 829 832 CML CML NNP 833 841 patients patient NNS 841 842 . . . 843 850 However however RB 850 851 , , , 852 856 this this DT 857 863 factor factor NN 864 872 appeared appear VBD 873 877 when when WRB 878 881 the the DT 882 885 CML CML NNP 886 894 patients patient NNS 895 903 achieved achieve VBD 904 912 complete complete JJ 913 927 haematological haematological JJ 928 937 remission remission NN 938 939 ( ( ( 939 942 CHR CHR NNP 942 943 ) ) ) 944 951 through through IN 952 968 alpha-interferon alpha-interferon NN 969 976 therapy therapy NN 976 977 . . . 978 985 Further further RB 985 986 , , , 987 989 an an DT 990 997 inverse inverse JJ 998 1010 relationship relationship NN 1011 1014 was be VBD 1015 1019 also also RB 1020 1028 observed observe VBN 1029 1036 between between IN 1037 1043 sterol sterol NN 1044 1053 modulated modulate VBD 1054 1066 LDL-receptor LDL-receptor NNP 1067 1071 gene gene NN 1072 1085 transcription transcription NN 1086 1089 and and CC 1090 1093 the the DT 1094 1101 binding binding NN 1102 1110 affinity affinity NN 1111 1113 of of IN 1114 1118 this this DT 1119 1121 47 47 CD 1122 1125 kDa kda NN 1126 1132 factor factor NN 1133 1135 to to TO 1136 1139 the the DT 1140 1143 SRE SRE NNP 1144 1152 sequence sequence NN 1152 1153 . . . 1154 1159 Based base VBN 1160 1164 upon upon IN 1165 1170 these these DT 1171 1178 results result NNS 1179 1181 we we PRP 1182 1189 propose propose VBP 1190 1194 that that IN 1195 1211 alpha-interferon alpha-interferon NN 1212 1219 through through IN 1220 1223 its its PRP$ 1224 1232 receptor receptor NN 1233 1242 initiates initiate VBZ 1243 1255 phosphatidic phosphatidic JJ 1256 1260 acid acid NN 1261 1270 dependent dependent JJ 1271 1281 signalling signalling NN 1282 1287 which which WDT 1288 1290 in in IN 1291 1295 turn turn NN 1296 1305 regulates regulate VBZ 1306 1309 the the DT 1310 1318 affinity affinity NN 1319 1321 of of IN 1322 1324 47 47 CD 1325 1328 kDa kda NN 1329 1335 sterol sterol NN 1336 1346 regulatory regulatory JJ 1347 1354 element element NN 1355 1362 binding binding NN 1363 1369 factor factor NN 1370 1372 as as RB 1373 1377 well well RB 1378 1380 as as IN 1381 1393 LDL-receptor LDL-receptor NNP 1394 1398 gene gene NN 1399 1412 transcription transcription NN 1413 1415 in in IN 1416 1427 lymphocytes lymphocyte NNS 1428 1432 from from IN 1433 1436 CML CML NNP 1437 1445 patients patient NNS 1445 1446 . . .